[Management Commentary & Strategic Update](index=1&type=section&id=Management%20Commentary%20%26%20Strategic%20Update) Stereotaxis reported Q1 2024 progress with revenue growth, increased system orders, and innovation advancements, expecting profitability - Received **two Genesis system orders**, increasing the system backlog[3](index=3&type=chunk) - Acquired APT to gain valuable commercial synergies and strategic strength[3](index=3&type=chunk) - Regulatory submissions for the MAGiC catheter were completed in Europe and the United States during Q1[3](index=3&type=chunk) - A new, smaller robot is progressing with regulatory submissions expected in Q2 2024, anticipating European clearance mid-year and FDA clearance in H2[3](index=3&type=chunk) - The company expects to launch a new guidewire, a product ecosystem in China, and a digital surgery solution later in 2024[3](index=3&type=chunk) [Q1 2024 Financial Performance](index=1&type=section&id=Q1%202024%20Financial%20Performance) Stereotaxis reported Q1 2024 total revenue of **$6.9 million** (+**5%**), a **58% gross margin**, and narrowed operating and net losses [Revenue Analysis](index=1&type=section&id=Revenue%20Analysis) Q1 2024 revenue increased by **5%** year-over-year, primarily driven by a **44.4%** rise in system revenue Q1 2024 Revenue vs. Q1 2023 (in millions) | Revenue Category | Q1 2024 | Q1 2023 | Change | % Change | | :--- | :--- | :--- | :--- | :--- | | System Revenue | $2.6 | $1.8 | +$0.8 | +44.4% | | Recurring Revenue | $4.3 | $4.7 | -$0.4 | -8.5% | | **Total Revenue** | **$6.9** | **$6.5** | **+$0.4** | **+5.0%** | [Profitability Analysis](index=1&type=section&id=Profitability%20Analysis) Stereotaxis achieved a **58% total gross margin** in Q1 2024, with significant reductions in operating and net losses Q1 2024 Gross Margin | Margin Category | Q1 2024 | | :--- | :--- | | Total Gross Margin | 58% | | Recurring Revenue Gross Margin | 76% | | System Gross Margin | 27% | Q1 2024 Loss Summary vs. Q1 2023 (in millions) | Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Operating Loss | ($4.7) | ($5.6) | | Net Loss | ($4.5) | ($5.3) | | Adjusted Operating Loss* | ($2.2) | ($3.0) | | Adjusted Net Loss* | ($1.9) | ($2.7) | - Adjusted operating expenses, excluding non-cash stock compensation, decreased to **$6.1 million** from **$6.9 million** year-over-year[5](index=5&type=chunk) [Financial Position and Outlook](index=2&type=section&id=Financial%20Position%20and%20Outlook) Stereotaxis maintains a strong financial position with **$18.2 million** cash and no debt, expecting profitability without additional financing [Balance Sheet and Liquidity](index=2&type=section&id=Balance%20Sheet%20and%20Liquidity) As of March 31, 2024, Stereotaxis held **$18.2 million** cash and no debt, with **($2.3) million** negative free cash flow - As of March 31, 2024, the company held **$18.2 million** in cash and cash equivalents with no debt[7](index=7&type=chunk) - Negative free cash flow for Q1 was **($2.3) million**[6](index=6&type=chunk) [Full-Year 2024 Outlook](index=2&type=section&id=Full-Year%202024%20Outlook) Stereotaxis reaffirms **double-digit revenue growth** for FY2024 and anticipates reaching profitability without additional financing - The company maintains its expectation of **double-digit revenue growth** for the full year 2024, excluding APT acquisition contributions[8](index=8&type=chunk) - Stereotaxis anticipates a lower rate of cash utilization and believes its balance sheet is sufficient to reach profitability without additional financing[9](index=9&type=chunk) [Consolidated Financial Statements](index=3&type=section&id=Consolidated%20Financial%20Statements) This section presents Stereotaxis, Inc.'s unaudited consolidated Q1 2024 financial statements, including Statements of Operations and Balance Sheets [Statements of Operations (Unaudited)](index=3&type=section&id=STEREOTAXIS%2C%20INC.%20STATEMENTS%20OF%20OPERATIONS) The unaudited Statements of Operations detail Stereotaxis's revenue, gross margin, operating expenses, and net loss for Q1 2024 and 2023 Three Months Ended March 31, (in thousands) | Description | 2024 | 2023 | | :--- | :--- | :--- | | Total revenue | $6,880 | $6,548 | | Gross margin | $3,966 | $3,876 | | Total operating expenses | $8,712 | $9,495 | | Operating loss | ($4,746) | ($5,619) | | Net loss | ($4,507) | ($5,347) | | Net loss attributable to common stockholders | ($4,838) | ($5,678) | | Net loss per share (Basic & Diluted) | ($0.06) | ($0.07) | [Balance Sheets (Unaudited)](index=4&type=section&id=STEREOTAXIS%2C%20INC.%20BALANCE%20SHEETS) The unaudited Balance Sheets present Stereotaxis's financial position, including cash, assets, liabilities, and equity as of March 31, 2024 Balance Sheet Highlights (in thousands) | Description | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | Cash and cash equivalents | $17,633 | $19,818 | | Total current assets | $31,208 | $33,267 | | **Total assets** | **$39,452** | **$41,909** | | Total current liabilities | $12,852 | $13,247 | | **Total liabilities** | **$19,421** | **$19,989** | | **Total stockholders' equity** | **$14,567** | **$16,343** |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS, INC. (Exact name of the Registrant as Specified in its Charter) DELAWARE 94-3120386 (State or Other Jurisdiction o ...

Financial Data and Key Metrics Changes - Revenue for the full year 2023 totaled $26.8 million, a decrease from $28.1 million in 2022 [36] - Gross margin for the fourth quarter and full year 2023 were approximately 60% and 56% of revenue, with full year gross margins of 79% on recurring revenue and 8% for system revenue [15][36] - Operating loss for the fourth quarter of 2023 was $5.3 million compared to $4.5 million in the previous year [37] - Adjusted operating loss for the full year 2023 was $11.3 million compared to $8.3 million in the prior year [133] Business Line Data and Key Metrics Changes - System revenue for the full year was $8.7 million compared to $6.8 million in the prior year, reflecting increased system deliveries and installations [132] - Recurring revenue for the full year was $18 million compared to $21.3 million, impacted by the absence of J&J royalties and periodic catheter shortages [132][130] Market Data and Key Metrics Changes - The company began 2024 with a backlog of $14.7 million from orders that were received but not yet shipped or installed [12] - The company expects recurring revenue to remain stable until the MAGiC catheter can contribute to disposable revenue growth [17] Company Strategy and Development Direction - The company is focused on addressing structural weaknesses in its product ecosystem and has developed a proprietary ablation catheter, the MAGiC catheter, to enhance its offerings [6][27] - The company plans to leverage its collaboration with MicroPort to establish a China-specific EP product ecosystem and expects regulatory approval for the Genesis robot in China midyear [127] - The company aims for a full launch of its digital surgery platform, Sync, to enhance operating room connectivity [10][32] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that progress has taken longer than expected but sees key regulatory submissions and technology developments aligning this year [11] - The company expects overall double-digit revenue growth for 2024 driven by system revenue growth from its backlog and new orders [17] - Management expressed confidence in the regulatory submissions for the MAGiC catheter and anticipates a collaborative review process with the FDA [64][90] Other Important Information - The company has a strong balance sheet with approximately $20 million in cash and no debt, allowing it to advance its product ecosystem to market [13][16] - The company has invested in significant inventory and has direct commercial teams globally to launch new products as they become available [105] Q&A Session All Questions and Answers Question: What is the outlook for MAGiC catheter submissions? - The EU submission is a resubmission with additional clinical data, and the company expects a more efficient review process [19][110] Question: How quickly can the company ramp up manufacturing for MAGiC? - The company has demonstrated capability to scale manufacturing and produced nearly 1,000 units during regulatory testing [73] Question: What is the plan for the sales force with the MAGiC launch? - The existing sales teams will be utilized for the MAGiC launch, with incremental hiring planned as revenue grows [82][150] Question: What is the expected revenue for the first quarter of 2024? - The company expects revenue of approximately $7 million for the first quarter of 2024 [134]

Exhibit 99.1 Stereotaxis Reports 2023 Full Year Financial Results ST. LOUIS, MO, Mar. 4, 2024 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2023. "We enter 2024 having made significant progress in realizing our strategic transformation. This is the year in which we expect all the key puzzle pieces to come together, setting ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS, INC. (Exact name of the Registrant as Specified in its Charter) DELAWARE 94-3120386 (State or Other Juris ...

Financial Data and Key Metrics Changes - Revenue for Q3 2023 totaled $7.8 million, up 2% from $7.7 million in the prior year [24] - Operating loss and net loss for Q3 were $5.6 million and $5.4 million, compared to $5.1 million and $4.9 million in the previous year [5] - Gross margin for Q3 2023 was 52% of revenue, with recurring revenue gross margin at 80% and system gross margin at 18% [25] - Negative free cash flow for Q3 was $1 million, with cash and cash equivalents at $23 million and no debt [6] Business Line Data and Key Metrics Changes - System revenue of $3.5 million reflects revenue recognition on the delivery of two Genesis systems [24] - Recurring revenue for the quarter was $4.3 million, predominantly impacted by the absence of J&J royalty and residual pressure on procedures [24] - The company recognized revenue from the adoption of Genesis by both Greenfield new accounts and existing upgrade customers [13] Market Data and Key Metrics Changes - The company has seen strengths in capital activity out of Europe, benefiting from enhanced commercial leadership and greater market appreciation for upcoming innovations [14] - In contrast, several projects in China have been delayed due to a countrywide anti-corruption drive, freezing hospital capital purchasing activity [15] Company Strategy and Development Direction - The company is actively driving a broad-based comprehensive innovation strategy forward, including the development of MAGiC and a smaller self-shielding robot [2][16] - The innovation strategy aims to expand the clinical use of the robotic platform beyond electrophysiology to various endovascular procedures [22] - The company plans to submit a PMA supplement for MAGiC using existing data, aiming to accelerate access for US physicians and patients [18] Management's Comments on Operating Environment and Future Outlook - Management remains confident in the ability to advance the innovation strategy to market and reach profitability without additional financings [8] - The company acknowledges the importance of maintaining financial strength in the current macro environment while delivering commercial results [8] - Management expressed optimism about the impact of the innovation strategy and the potential for growth beyond the current backlog [1][24] Other Important Information - The company has a cash balance expectation of $22 million by year-end with no debt [6] - The company is working on regulatory submissions for MAGiC and expects to receive responses from European health authorities soon [17] Q&A Session Questions and Answers Question: What is being done differently in Europe to drive increased activity? - The new leadership in Europe has implemented a disciplined process and is leveraging product ecosystem aspects, including the anticipation of MAGiC approval [28] Question: Can you clarify the expectations for revenue growth in 2023? - Management indicated that while they are confident in growth in the coming quarters, they are not certain about achieving annualized double-digit revenue growth based on fourth-quarter results [46] Question: What is the timeline for collecting data in Europe for MAGiC? - The trial is structured to capture acute clinical data from 20 patients, with the potential to enroll up to 30 patients at each of the three sites [67] Question: How does the company view the replacement cycle for its systems? - A significant majority of the installed base is over 10 years old, indicating a ripe opportunity for replacement, although the replacement cycle is still tied to X-ray system replacements [65][66]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS, INC. (Exact name of the Registrant as Specified in its Charter) DELAWARE 94-3120386 (State or Other Jurisdicti ...

Stereotaxis, Inc. (NYSE:STXS) Q2 2023 Earnings Conference Call August 10, 2023 10:00 AM ET Company Participants David Fischel - Chairman & Chief Executive Officer Kimberly Peery - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Adam Maeder - Piper Sandler Alex Nowak - Craig-Hallum Capital Josh Jennings - TD Cowen Neil Chatterji - B. Riley Securities Operator Good morning. Thank you for joining us for Stereotaxis' Second Quarter 2023 Earnings Conference Call. ...

Part I Financial Information [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) The unaudited consolidated financial statements for Q1 2023 show a net loss of **$5.3 million**, with total assets decreasing to **$50.7 million** [Balance Sheets](index=4&type=section&id=Balance%20Sheets) Total assets decreased to **$50.7 million** by March 31, 2023, driven by reduced cash, and equity declined to **$23.7 million** Consolidated Balance Sheet Summary (in thousands) | Account | March 31, 2023 (USD) | December 31, 2022 (USD) | | :--- | :--- | :--- | | **Current Assets** | | | | Cash and cash equivalents | $5,623 | $8,586 | | Short-term investments | $20,041 | $19,844 | | Total current assets | $40,905 | $43,246 | | **Total Assets** | **$50,711** | **$53,413** | | **Current Liabilities** | | | | Total current liabilities | $14,269 | $14,291 | | **Total Liabilities** | **$21,418** | **$21,484** | | **Total Stockholders' Equity** | **$23,710** | **$26,346** | | **Total Liabilities and Stockholders' Equity** | **$50,711** | **$53,413** | [Statements of Operations](index=5&type=section&id=Statements%20of%20Operations) Q1 2023 total revenue decreased **7%** to **$6.5 million**, leading to a **$5.6 million** operating loss and **$5.7 million** net loss Statement of Operations Summary (in thousands, except per share data) | Metric | Q1 2023 (USD) | Q1 2022 (USD) | | :--- | :--- | :--- | | Total Revenue | $6,548 | $7,037 | | Gross Margin | $3,876 | $4,924 | | Total Operating Expenses | $9,495 | $9,013 | | Operating Loss | $(5,619) | $(4,089) | | Net Loss | $(5,347) | $(4,086) | | Net Loss per Share (Basic & Diluted) | $(0.07) | $(0.06) | [Statements of Cash Flows](index=8&type=section&id=Statements%20of%20Cash%20Flows) Net cash used in operating activities increased to **$2.8 million** in Q1 2023, with total cash balances decreasing to **$6.8 million** Cash Flow Summary (in thousands) | Cash Flow Activity | Three Months Ended March 31, 2023 (USD) | Three Months Ended March 31, 2022 (USD) | | :--- | :--- | :--- | | Net cash used in operating activities | $(2,802) | $(2,193) | | Net cash used in investing activities | $(349) | $(1,154) | | Net cash provided by financing activities | $56 | $54 | | **Net decrease in cash, cash equivalents, and restricted cash** | **$(3,095)** | **$(3,293)** | [Notes to Financial Statements](index=9&type=section&id=Notes%20to%20Financial%20Statements) Notes detail business operations, accounting policies, cardiac ablation focus, supply chain risks, and stock-based compensation - The company's primary products are the Genesis RMN System and the Odyssey Solution, focusing on cardiac ablation procedures for arrhythmias, with an aspiration to expand into other endovascular indications[25](index=25&type=chunk)[27](index=27&type=chunk) - The company continues to face risks from supply chain disruptions, inflation, and hospital staffing shortages, which can impact procedure volumes, system installations, and operating costs[37](index=37&type=chunk)[38](index=38&type=chunk)[40](index=40&type=chunk) - In April 2023, all outstanding shares of Series B Convertible Preferred Stock were converted into common stock on a one-for-one basis[96](index=96&type=chunk) - The company has a 10-year CEO Performance Award of up to **13 million shares** tied to market capitalization milestones. Stock-based compensation expense for this award was **$1.8 million** in Q1 2023[98](index=98&type=chunk)[103](index=103&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=28&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) MD&A highlights a **7% revenue decrease** to **$6.5 million** in Q1 2023, lower gross margin, and **$26.8 million** liquidity [Results of Operations](index=33&type=section&id=Results%20of%20Operations) Q1 2023 revenue decreased **7%** to **$6.5 million**, driven by lower disposables and service revenue, with gross margin at **59%** Revenue Comparison (in millions) | Revenue Stream | Q1 2023 (USD) | Q1 2022 (USD) | Change | | :--- | :--- | :--- | :--- | | Systems | $1.8 | $1.6 | +12.5% | | Disposables, service, and accessories | $4.7 | $5.4 | -13.0% | | **Total Revenue** | **$6.5** | **$7.0** | **-7.0%** | - The decrease in disposables, service, and accessories revenue was primarily driven by lower royalties from Biosense Webster[151](index=151&type=chunk) - Gross margin decreased to **59%** in Q1 2023 from **70%** in Q1 2022, driven by changes in system product mix and increased costs under service contracts[152](index=152&type=chunk) - Operating expenses increased, with R&D up **12%** due to project timing and regulatory expenses, and Sales & Marketing up **7%** from higher travel and stock-based compensation[153](index=153&type=chunk)[154](index=154&type=chunk) [Liquidity and Capital Resources](index=35&type=section&id=Liquidity%20and%20Capital%20Resources) The company maintains strong liquidity with **$6.8 million** in cash and **$20.0 million** in short-term investments, holding no debt Liquidity Position (in millions) | Metric | March 31, 2023 (USD) | December 31, 2022 (USD) | | :--- | :--- | :--- | | Cash, cash equivalents, and restricted cash | $6.8 | $9.9 | | Short-term investments | $20.0 | $19.8 | | Working Capital | $26.6 | $29.0 | - Net cash used in operating activities increased to **$2.8 million** in Q1 2023 from **$2.2 million** in Q1 2022, driven by a higher operating loss[159](index=159&type=chunk) - The company had no debt as of March 31, 2023[162](index=162&type=chunk) [Controls and Procedures](index=35&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective as of March 31, 2023, with no material internal control changes - Management, including the CEO and CFO, concluded that the company's disclosure controls and procedures were effective as of March 31, 2023[165](index=165&type=chunk) - No material changes to the company's internal control over financial reporting were identified during the first quarter of 2023[166](index=166&type=chunk) Part II Other Information [Legal Proceedings](index=36&type=section&id=Item%201.%20Legal%20Proceedings) The company reported no material legal proceedings during the period - The company reports no material legal proceedings[168](index=168&type=chunk) [Risk Factors](index=36&type=section&id=Item%201A.%20Risk%20Factors) Updated risk factors highlight exposure to uninsured cash balances, with minimal impact from the SVB failure - The company highlights the risk of maintaining cash balances in excess of FDIC-insured limits at financial institutions[169](index=169&type=chunk) - Following the failure of Silicon Valley Bank (SVB), the company stated its cash balance at SVB was less than **6%** of its total cash and investments and it does not believe it has exposure to loss[169](index=169&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=36&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales of equity securities were reported during the period - None reported[170](index=170&type=chunk)

Stereotaxis, Inc. (NYSE:STXS) Q1 2023 Earnings Conference Call May 9, 2023 10:00 AM ET Company Participants David Fischel - CEO & Chairman Kimberly Peery - CFO & Secretary Conference Call Participants Joshua Jennings - TD Cowen Frank Takkinen - Lake Street Capital Markets Alexander Nowak - Craig-Hallum Capital Group Neil Chatterji - B. Riley Securities Adam Maeder - Piper Sandler Operator Good morning. Thank you for joining us for Stereotaxis' First Quarter 2023 Earnings Conference Call. Certain statements ...